Adma Biologics (ADMA) Other Non-Current Assets (2011 - 2026)
Adma Biologics' (ADMA) quarterly Other Non-Current Assets came in at $8.6 million in Q4 2025, up 52.02% YoY from $5.7 million in Q4 2024, and down 2.25% on a QoQ basis from $8.8 million in Q3 2025.
Adma Biologics (ADMA) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Other Non-Current Assets data on file, last reported at $8.6 million in Q4 2025.
- Quarterly Other Non-Current Assets rose 52.02% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.6 million (up 52.02% YoY) and the FY2025 annual result came in at $8.6 million, up 52.02% from the prior year.
- Other Non-Current Assets eased to $8.6 million in Q4 2025, from $8.8 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $9.1 million in Q2 2025 to a low of $2.2 million in Q1 2021.
- A 5-year average of $5.4 million and a median of $5.0 million in 2022 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 93.04% in 2021, down 35.85% in 2021.
- Tracing ADMA's Other Non-Current Assets over 5 years: stood at $4.1 million in 2021, then grew by 17.27% to $4.8 million in 2022, then declined by 2.1% to $4.7 million in 2023, then climbed by 21.13% to $5.7 million in 2024, then surged by 52.02% to $8.6 million in 2025.
- The last three Other Non-Current Assets figures came in at $8.6 million (Q4 2025), $8.8 million (Q3 2025), and $9.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 9.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.13 Mn |
| Dec 31, 2025 | 8.60 Mn |
| Sep 30, 2025 | 8.80 Mn |
| Jun 30, 2025 | 9.06 Mn |
| Mar 31, 2025 | 8.19 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | 5.82 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.89 Mn |
| Dec 31, 2023 | 4.67 Mn |
| Sep 30, 2023 | 6.72 Mn |
| Jun 30, 2023 | 6.29 Mn |
| Mar 31, 2023 | 4.72 Mn |
| Dec 31, 2022 | 4.77 Mn |
| Sep 30, 2022 | 4.46 Mn |
| Jun 30, 2022 | 3.76 Mn |
| Mar 31, 2022 | 2.83 Mn |
| Dec 31, 2021 | 4.07 Mn |
| Sep 30, 2021 | 3.33 Mn |
| Jun 30, 2021 | 2.53 Mn |